Charles Dayen1, Didier Debieuvre2, Olivier Molinier3, Olivier Raffy4, Fabrice Paganin5, Jérôme Virally6, Sébastien Larive7, Béatrice Desurmont-Salasc8, Marielle Perrichon9, Francis Martin10, Michel Grivaux11. 1. Respiratory Medicine Department, Hôpital de Saint-Quentin, Saint-Quentin, France. 2. Respiratory Medicine Department, Groupe Hospitalier de la Région Mulhouse Sud-Alsace, Hôpital Émile Muller, Mulhouse, France. 3. Respiratory Medicine Department, Hôpital du Mans, Le Mans, France. 4. Respiratory Medicine Department, Hôpital Louis Pasteur, Le Coudray, France. 5. Respiratory Medicine Department, Hôpital Sud de La Réunion, Saint-Pierre, France. 6. Respiratory Medicine Department, Centre Hospitalier Intercommunal Robert Ballanger, Aulnay-sous-Bois, France. 7. Respiratory Medicine Department, Hôpital Les Chanaux, Mâcon, France. 8. Respiratory Medicine Department, Centre Hospitalier Intercommunal de Frejus-Saint-Raphaël, Saint-Raphaël, France. 9. Respiratory Medicine Department, Hôpital Fleyriat, Bourg-en-Bresse, France. 10. Pneumology and Sleep Disorders Department, Centre Hospitalier Intercommunal de Compiègne-Noyon, Compiègne cedex, France. 11. Respiratory Medicine Department, Hôpital de Meaux, Meaux, France.
Abstract
BACKGROUND: The French College of General Hospital Respiratory Physicians conducted two studies that consecutively included all patients followed in participating general hospitals for primary small cell (SCLC) or non-small cell (NSCLC) lung cancer diagnosed in 2000 and 2010. These studies allow descriptive statistics and outcome assessment for SCLC and NSCLC separately and comparison over a 10-year period. METHODS: A standardised form was completed for each patient at inclusion. Then, vital status was collected. RESULTS: In 2000 and 2010, 948 (15.5% female) and 968 (23.3%) SCLC patients, mainly heavy active- or former-smoker seniors, participated in these studies. One-year survival rate was 35.8% for SCLC vs. 44.8% for NSCLC in 2010 and 33.1% for SCLC in 2000. In 2010, in reference to stage 0-IIB (4.1% of SCLCs), the hazard ratio was 0.92 [95% confidence interval (CI): 0.6-1.5; P=0.76], 1.8 (95% CI: 1.1-2.8; P=0.019), and 3.4 (95% CI: 2.2-5.3; P<0.001) for stage IIIA (10.2%), IIIB (14.5%), and IV (71.2%). Positron emission tomography (PET)-scan use, which has increased in 10 years, was frequent in patients with limited disease. CONCLUSIONS: One-year survival in SCLC patients was poor in 2010 and dependent of SCLC stage. TNM classification reintroduction and new diagnostic techniques (e.g., PET-scan) should allow lung oncologists to tailor treatment based on disease stage at diagnosis.
BACKGROUND: The French College of General Hospital Respiratory Physicians conducted two studies that consecutively included all patients followed in participating general hospitals for primary small cell (SCLC) or non-small cell (NSCLC) lung cancer diagnosed in 2000 and 2010. These studies allow descriptive statistics and outcome assessment for SCLC and NSCLC separately and comparison over a 10-year period. METHODS: A standardised form was completed for each patient at inclusion. Then, vital status was collected. RESULTS: In 2000 and 2010, 948 (15.5% female) and 968 (23.3%) SCLC patients, mainly heavy active- or former-smoker seniors, participated in these studies. One-year survival rate was 35.8% for SCLC vs. 44.8% for NSCLC in 2010 and 33.1% for SCLC in 2000. In 2010, in reference to stage 0-IIB (4.1% of SCLCs), the hazard ratio was 0.92 [95% confidence interval (CI): 0.6-1.5; P=0.76], 1.8 (95% CI: 1.1-2.8; P=0.019), and 3.4 (95% CI: 2.2-5.3; P<0.001) for stage IIIA (10.2%), IIIB (14.5%), and IV (71.2%). Positron emission tomography (PET)-scan use, which has increased in 10 years, was frequent in patients with limited disease. CONCLUSIONS: One-year survival in SCLC patients was poor in 2010 and dependent of SCLC stage. TNM classification reintroduction and new diagnostic techniques (e.g., PET-scan) should allow lung oncologists to tailor treatment based on disease stage at diagnosis.
Entities:
Keywords:
Epidemiology; France; general; hospitals; mortality; small cell lung cancer (SCLC); stage
Authors: Shervin M Shirvani; Ritsuko Komaki; John V Heymach; Frank V Fossella; Joe Y Chang Journal: Int J Radiat Oncol Biol Phys Date: 2011-04-12 Impact factor: 7.038
Authors: David Schreiber; Justin Rineer; Jeremy Weedon; Dan Vongtama; Angela Wortham; Anne Kim; Peter Han; Kwang Choi; Marvin Rotman Journal: Cancer Date: 2010-03-01 Impact factor: 6.860
Authors: I Brink; T Schumacher; M Mix; S Ruhland; E Stoelben; W Digel; M Henke; N Ghanem; E Moser; E U Nitzsche Journal: Eur J Nucl Med Mol Imaging Date: 2004-07-17 Impact factor: 9.236
Authors: Robert Chin; Trent W McCain; Antonius A Miller; Donnie P Dunagan; Jose Acostamadiedo; L Douglas Case; Beth A Harkness; Lee P Adler; Edward F Haponik Journal: Lung Cancer Date: 2002-07 Impact factor: 5.705
Authors: F Blanchon; M Grivaux; T Collon; M Zureik; H Barbieux; M Bénichou-Flurin; J L Breton; D Coëtmeur; B Delclaux; B Asselain; J Piquet Journal: Rev Mal Respir Date: 2002-12 Impact factor: 0.622
Authors: Vinicius Cavalheri; Chris Burtin; Vittoria R Formico; Mika L Nonoyama; Sue Jenkins; Martijn A Spruit; Kylie Hill Journal: Cochrane Database Syst Rev Date: 2019-06-17